6.56
Wave Life Sciences Ltd stock is traded at $6.56, with a volume of 1.51M.
It is up +7.19% in the last 24 hours and down -31.60% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$6.12
Open:
$6.13
24h Volume:
1.51M
Relative Volume:
1.33
Market Cap:
$963.89M
Revenue:
$53.61M
Net Income/Loss:
$-142.52M
P/E Ratio:
-5.9099
EPS:
-1.11
Net Cash Flow:
$-141.83M
1W Performance:
+4.46%
1M Performance:
-31.60%
6M Performance:
-55.77%
1Y Performance:
+35.54%
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
WVE
Wave Life Sciences Ltd
|
6.56 | 963.89M | 53.61M | -142.52M | -141.83M | -1.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-08-25 | Initiated | Wedbush | Outperform |
Feb-25-25 | Initiated | Jefferies | Buy |
Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-27-24 | Resumed | JP Morgan | Overweight |
Sep-19-24 | Initiated | B. Riley Securities | Buy |
Sep-09-24 | Initiated | JP Morgan | Overweight |
May-15-24 | Initiated | Wells Fargo | Overweight |
Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
Jul-05-23 | Initiated | Raymond James | Outperform |
May-24-23 | Downgrade | Jefferies | Buy → Hold |
Dec-15-20 | Resumed | H.C. Wainwright | Buy |
Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Nov-01-19 | Initiated | Guggenheim | Buy |
Jul-15-19 | Initiated | Cowen | Market Perform |
Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
Aug-07-18 | Initiated | Stifel | Buy |
Jul-23-18 | Initiated | H.C. Wainwright | Buy |
Mar-19-18 | Reiterated | Mizuho | Buy |
Feb-15-17 | Initiated | H.C. Wainwright | Buy |
Nov-10-16 | Resumed | Leerink Partners | Outperform |
Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
Dec-07-15 | Initiated | Jefferies | Buy |
Dec-07-15 | Initiated | Leerink Partners | Outperform |
Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
(WVE) Investment Report - news.stocktradersdaily.com
Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely? - Yahoo Finance
Wave Life Sciences (NASDAQ:WVE) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
Wave Life Sciences (WVE) Price Target Reduced by B. Riley Amid F - GuruFocus
B. Riley Adjusts Wave Life Sciences' Price Target to $19 From $22, Keeps Buy Rating - MarketScreener
Wedbush sets $18 target for WAVE Life Sciences stock By Investing.com - Investing.com India
Wedbush sets $18 target for WAVE Life Sciences stock - Investing.com Australia
Wedbush Initiates Wave Life Sciences at Outperform With $18 Price Target - MarketScreener
(WVE) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 41% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - simplywall.st
RBC Cuts Price Target on Wave Life Sciences to $10 From $14, Keeps Sector Perform, Speculative Risk - MarketScreener
Wave Life Sciences’ SWOT analysis: RNA editing pioneer faces challenges in genetic medicine stock - Investing.com India
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
What is Leerink Partnrs’ Estimate for WVE Q1 Earnings? - Defense World
Promising Genomics & Synthetic Biology Stocks to Consider in 2025 - Yahoo Finance
HC Wainwright Reaffirms “Buy” Rating for Wave Life Sciences (NASDAQ:WVE) - Defense World
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531 (NASDAQ:WVE) - Seeking Alpha
WAVE Life Sciences stock holds buy rating, $22 target from H.C. Wainwright - Investing.com Australia
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531 - Yahoo Finance
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? - Nasdaq
Wave Life Sciences reports progress in DMD treatment By Investing.com - Investing.com Australia
Wave Aspires To Accelerated Approval In DMD With 48-Week Data - insights.citeline.com
Riding the Wave, exon skipper sails toward DMD filing - BioWorld Online
Sector Update: Health Care Stocks Retreat Wednesday Afternoon - MarketScreener
Jefferies maintains Buy on WAVE Life Sciences stock, $26 target By Investing.com - Investing.com South Africa
Wave Life Sciences to submit Duchenne drug for approval after Phase 2 success - The Boston Globe
Jefferies maintains Buy on WAVE Life Sciences stock, $26 target - Investing.com India
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year - Benzinga
Wave to seek FDA accelerated approval for Duchenne candidate in 2026 - MSN
Wave Life Sciences shares surge on positive DMD trial results By Investing.com - Investing.com Australia
Wave Life Sciences shares surge on positive DMD trial results - Investing.com
Wave Life Sciences reports progress in DMD treatment - Investing.com India
Wave Life Sciences Reports Positive Phase 2 Trial Results - TipRanks
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD - MarketScreener
Wave Life Sciences Announces Positive Data from FORWARD-53 - GlobeNewswire
Clinical Trial Breakthrough: New DMD Drug Achieves Unprecedented Muscle Recovery - StockTitan
Victory Capital Management Inc. Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Charles Schwab Investment Management Inc. Grows Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences director Christian Henry sells $102,574 in shares By Investing.com - Investing.com South Africa
Wave Life Sciences director Christian Henry sells $102,574 in shares - Investing.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Bank of New York Mellon Corp - Defense World
Adma Biologics (ADMA) Surges 10.2%: Is This an Indication of Further Gains? - Yahoo Finance
US Bancorp DE Cuts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Arizona State Retirement System Acquires 7,846 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
How To Trade (WVE) - Stock Traders Daily
Wave Life Sciences’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com
Mizuho maintains WAVE Life Sciences Outperform rating By Investing.com - Investing.com India
Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Paul Bolno Sells 169,025 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock - Defense World
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):